Essity Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Essity Bundle
Actionable Strategy Starts Here
Essity’s BCG Matrix preview shows where its brands sit—market leaders, resource-drainers, or risky bets—and hints at the moves you should consider next. Want the full picture? Purchase the complete BCG Matrix for quadrant-by-quadrant placements, data-backed recommendations, and ready-to-use Word and Excel files that let you act fast and present with confidence.
Stars
TENA incontinence leadership
TENA, Essity's market-leading continence brand, holds massive share and clinical credibility, putting it in pole position. Global 65+ population is about 10% today and projected by the UN to reach 16% by 2050, driving fast category growth and rising awareness. The segment attracts heavy investment in education, clinical trials and retail presence. Continued investment will convert growth into a larger cash engine.
Tork professional hygiene systems
Tork owns the premium system-based B2B dispenser space—locking repeat refills across offices, healthcare and foodservice as post‑COVID hygiene standards persist. As Essity’s professional hygiene brand within Stockholm‑based Essity (about 45,000 employees), scaling Tork requires capex, channel push and data‑backed selling. Holding share today compacts into a dependable cash cow later.
IoT-enabled cleaning (Tork Vision Cleaning)
Tork Vision Cleaning, launched 2018, uses sensors and data dashboards to cut complaints and enable facilities to pay for performance; the nascent but fast-growing wedge deepens customer stickiness. It requires focused sales activation, systems integrations and documented proofs of ROI to scale. Scale now to monetize refill pull-through and recurring consumable revenue for years.
Fem-care in growth markets (Libresse/Bodyform/Nosotras)
Penetration and premiumization in emerging markets rose markedly by 2024, with femcare premium segment growing an estimated 6–9% CAGR versus mature markets; Libresse/Bodyform/Nosotras leverage strong brand equity and innovations in comfort, skin-friendly materials and sustainability to lift share.
Heavy media and shopper investments—often 10–20% higher spend per incremental market—drive adoption; strategy is win now, harvest later as adoption curves begin to flatten.
- Penetration up 2024: premium CAGR ~6–9%
- Brand-led share gains via comfort/skin/sustainability
- Media/shopper spend +10–20% to accelerate conversion
- Play: invest aggressively now, harvest as curve flattens
Incontinence home-care channels
In Essity’s BCG matrix Stars: Incontinence home-care channels are fast-growing as the shift from institutional to at-home care accelerates; the global adult incontinence market was valued at about USD 9.1 billion in 2023 with double-digit home-care uptake. DTC, e-commerce and subscription models raise lifetime value and margins as e-commerce penetration for health products approached ~20% in 2024. Education and sampling are investment-heavy but convert well, locking users early and creating a strong retention flywheel.
- Market: USD 9.1bn (2023)
- E-commerce ~20% penetration (2024)
- DTC/subscription: higher LTV, improved margins
- Education/sampling: high CAC but strong conversion
Scale DTC, subscriptions & data to win recurring revenue from USD 9.1bn incontinence market
Stars: TENA and Tork lead fast-growing home-care and B2B hygiene segments—adult incontinence market USD 9.1bn (2023) with e‑commerce ~20% (2024). Global 65+ ~10% (2024), UN 16% by 2050, driving demand; femcare premium CAGR ~6–9% to 2024. Invest to scale DTC, subscriptions and Tork Vision data services to capture recurring revenue and harvest later.
| Metric | Value |
|---|---|
| Incontinence market (2023) | USD 9.1bn |
| E‑commerce (2024) | ~20% |
| 65+ population (2024) | ~10% |
| Femcare premium CAGR | 6–9% |
What is included in the product
Detailed Word Document
Comprehensive Essity BCG Matrix review with strategic advice for Stars, Cash Cows, Question Marks and Dogs, plus investment guidance.
Customizable Excel Spreadsheet
One-page Essity BCG Matrix simplifying portfolio choices and spotlighting where to invest, divest or focus
Cash Cows
European consumer tissue (Tempo, Lotus, Zewa, Cushelle, Edet)
European consumer tissue (Tempo, Lotus, Zewa, Cushelle, Edet) is a mature category with household penetration above 90% in 2024 and stable share across core markets. Strong brands and shelf positions produce steady cash flow, limiting the need for heavy promotion beyond price hygiene. Invest in manufacturing and distribution efficiency and milk margins through cost optimisation.
Tork refill consumables in mature accounts
Locked-in Tork dispensers in mature Essity accounts deliver predictable repeat volumes and high refill attach rates, preserving revenue stability. Real switching costs keep price realization above commodity tissue, supporting margin resilience. With low market growth but high utilisation these accounts act as cash cows, generating steady annuity-like cash yield for Essity. Maintain premium service and the recurrent service contract economics continue to pay.
Libero baby diapers in core Nordics
Libero baby diapers face flat-to-declining birth rates in the core Nordics, with total fertility rate around 1.5 children per woman in 2024 (national statistics), but brand loyalty remains strong. Distribution is entrenched and promo cycles predictable, supporting steady off-take. Margins are reliable when managed via SKU mix; strategy: maintain brand, optimize plant utilization and protect shelf space.
Professional wiping and napkins for stable segments
Professional wiping and napkins in developed markets remain Cash Cows: 2024 developed-market foodservice and light industry volumes were roughly flat y/y, with predictable demand and ASP stability. The product set is standardized, delivering scale-driven gross margin durability and low R&D spend. Strategy: prioritize operations discipline, margin capture and free cash conversion rather than new big bets.
- Stable volumes 2024: ≈0%–2% y/y in developed markets
- Standardized SKUs → scale benefits, lower unit cost
- Low capex/R&D; focus on OPEX efficiency
- Cash-out approach: harvest margins, redeploy cash
Institutional incontinence tenders in mature Europe
Institutional incontinence tenders in mature Europe deliver large frameworks, predictable volumes and proven protocols; Essity leverages scale (Essity 2024 net sales ~130 billion SEK) to absorb price pressure, producing low growth but high repeat-buy cash flow and strong operating cash conversion.
- Renew contracts
- Streamline logistics
- Bank the returns
Operate for cash: protect premium channels, trim OPEX, secure major tenders
Essity cash cows: European consumer tissue (penetration >90% in 2024) and Tork dispensers yield steady cash flow; Libero diapers face TFR ~1.5 in Nordics but high loyalty; professional wiping and institutional incontinence show ≈0–2% y/y volumes in developed markets. Focus: operate-for-cash, cost/OPEX efficiency, protect premium channels and renew large tenders.
| Segment | 2024 metric | Growth | Strategy |
|---|---|---|---|
| Consumer tissue | Penetration >90% | ~0% | Margin ops |
| Tork | High refill attach | ~1% | Service premium |
| Libero | TFR 1.5 | Flat/decline | SKU mix |
| Wiping/Institutional | Stable volumes | 0–2% | Harvest cash |
What You’re Viewing Is Included
Essity BCG Matrix
The Essity BCG Matrix you're previewing on this page is the final document you'll receive after purchase. No watermarks, no demo content—just a fully formatted, analysis-ready report designed for strategic clarity. Once bought, the exact same file is instantly downloadable for editing, printing, or presenting to stakeholders. Clean, professional, and ready to plug into your planning process.
Dogs
Low-margin private-label tissue contracts
Low-margin private-label tissue contracts face commodity pricing with little brand leverage and heavy capex wear; Essity operates in 150+ countries and private-label can account for up to 40% of tissue volumes in Western markets (2024), tying working capital to thin pennies. Turnarounds rarely pay without scale—prune or reprice, don’t linger.
Under-scale regional brands in fragmented markets
Under-scale regional Dogs often sit below 3% market share with brand awareness under 20% and promotional intensity exceeding 20% of sales; national players command 60–80% share while private label penetration reached up to 30% in some European hygiene markets in 2024. They drain working capital and management focus, so consider exit or folding into stronger Essity banners to stop margin leakage.
Standalone wiping SKUs without system lock-in
Standalone wiping SKUs with no dispenser lock allow easy switching to the cheapest option, driving retailer price wars that erode margins rapidly. Essity reported net sales of SEK 129.1 billion in 2023, making sustained marketing burn on unlocked SKUs hard to justify versus higher-margin system-led ranges. Rationalize SKUs and redirect investment to dispenser-tied portfolios to protect margin and drive loyalty.
Legacy SKUs born from one-off COVID spikes
Legacy SKUs born from one-off COVID spikes now sit in a post-pandemic demand environment where volumes have normalized and inventory risk lingers across channels; retailers report tightened shelf space and rapid delistings as elasticity proves brutal, making paid activation inefficient. Sunset and simplify the range rather than revive with incremental marketing spend.
- Inventory risk: prolonged aging SKUs
- Retail action: space cuts, delist pressures
- Elasticity: weak demand response to price/promos
- Recommendation: sunset low-velocity SKUs, simplify portfolio
Non-differentiated value-tier fem-care lines
Non-differentiated value-tier fem-care is a Dogs segment: private label (≈33% share in EU grocery in 2023, Kantar) undercuts price with good-enough quality, making premium brand ad spend unable to close the value gap; margin at best breakeven, at worst a strategic distraction. Trim SKUs and refocus investment on premium fem-care where Essity has scale and innovation advantage.
- Private label pressure: ~33% EU grocery share (Kantar 2023)
- Brand spend ineffective vs price-led defections
- Action: prune value-tier, reallocate to premium R&D and marketing
Prune low-margin PL (up to 40%)—shift spend to dispenser-led premium
Low-margin private-label tissue and under-scale regional SKUs drain cash and working capital; private-label can be up to 40% of tissue volumes in Western markets (2024). Sunset/value-tier fem-care (~33% private-label share EU 2023) and redirect spend to dispenser-led and premium ranges. Prune SKUs, exit small markets, fold into strong banners.
| Metric | Value |
|---|---|
| Private-label tissue | up to 40% (2024) |
| Fem-care value-tier | ≈33% PL share (EU 2023) |
| Recommendation | Sunset/prune, fold to banners |
Question Marks
Modibodi reusable absorbent apparel
Modibodi, founded 2013, sits in Essitys Question Marks quadrant as reusable absorbent apparel benefits from a clear consumer shift to reusables while the category remains early-stage. The brand shows momentum and growing awareness but global share is still limited, requiring scale in retail distribution, consumer education, and fit innovation. Targeted investment can push Modibodi toward Star status.
Digital continence care services and telehealth tools
Digital continence services and companion apps can boost adherence and brand lock‑in by offering data‑driven care; urinary incontinence affects an estimated 200 million people worldwide, creating scale potential. Revenue models and payer acceptance remain nascent, pilots look promising but unproven at scale, so double down selectively where unit economics and reimbursement clarity pencil out.
Sustainable fiber innovations (e.g., alternative pulp)
Customers increasingly demand lower-footprint tissue and retailers require verified claims, pressuring Essity (net sales SEK 140.4 billion in 2023) to scale sustainable fiber innovations. Tech maturity, secure alternative-pulp sourcing and current cost curves remain key hurdles. If production costs fall materially, brand and retailer uptake could accelerate rapidly; back the winners and divest slow converters.
E-commerce subscriptions for hygiene bundles
E-commerce subscriptions for hygiene bundles are a strong fit for Essity’s incontinence and fem-care replenishment, offering predictable repeat revenue; 2024 subscription commerce saw continued acceleration with ~20% YoY growth in recurring D2C segments. CAC, churn and last-mile economics need tuning—benchmarks in 2024 showed median monthly churn ≈5% and D2C CAC ranges often $40–60. If LTV consistently exceeds CAC the quadrant flips to Star quickly; test, iterate, scale.
- Fit: replenishment-led retention
- Need: CAC, churn, last-mile
- 2024: subscription growth ≈20% YoY
- Trigger: LTV > CAC → Star
- Action: test, iterate, scale
Emerging markets tissue capacity expansions
Emerging markets tissue capacity expansions sit in Question Marks: UN estimates 56.9% urbanization in 2024, and IMF projected emerging market GDP growth ~4.3% in 2024, driving demand but competition is fierce and Essity’s early share is small while greenfield mill capex is heavy.
Route-to-market and distributor reach decide payback; invest selectively where brand or channel pricing power is defensible.
- Urbanization 56.9% (UN 2024)
- EM GDP growth ~4.3% (IMF 2024)
- High upfront mill capex; selective investment
Convert continence apps, tissue & D2C to stars - 200M, 20%
Modibodi (founded 2013), digital continence apps, sustainable tissue innovations and D2C subscriptions sit in Essity’s Question Marks; targeted capex and go‑to‑market scale can convert winners to Stars. Key metrics: Essity net sales SEK 140.4bn (2023), urinary incontinence ~200M people, subscription growth ~20% (2024).
| Asset | Signal | Trigger |
|---|---|---|
| Modibodi | early share, awareness | retail scale |
| Apps | 200M addressable | reimbursement |
| Subscriptions | ~20% YoY | LTV>CAC |